IL273407B2 - Methods and compositions for the treatment of epidermolysis bullosa - Google Patents

Methods and compositions for the treatment of epidermolysis bullosa

Info

Publication number
IL273407B2
IL273407B2 IL273407A IL27340720A IL273407B2 IL 273407 B2 IL273407 B2 IL 273407B2 IL 273407 A IL273407 A IL 273407A IL 27340720 A IL27340720 A IL 27340720A IL 273407 B2 IL273407 B2 IL 273407B2
Authority
IL
Israel
Prior art keywords
microvesicles
pharmaceutical composition
heterogeneous population
subject
polyethylene glycol
Prior art date
Application number
IL273407A
Other languages
English (en)
Hebrew (he)
Other versions
IL273407A (en
IL273407B1 (en
Inventor
Evangelos Badiavas
Original Assignee
Univ Miami
Evangelos Badiavas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US12558316B2/en
Application filed by Univ Miami, Evangelos Badiavas filed Critical Univ Miami
Publication of IL273407A publication Critical patent/IL273407A/en
Publication of IL273407B1 publication Critical patent/IL273407B1/en
Publication of IL273407B2 publication Critical patent/IL273407B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Water Treatments (AREA)
  • Medicinal Preparation (AREA)
IL273407A 2017-09-22 2018-09-21 Methods and compositions for the treatment of epidermolysis bullosa IL273407B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US12558316B2 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
PCT/US2018/052213 WO2019060719A1 (en) 2017-09-22 2018-09-21 METHODS AND COMPOSITIONS FOR THE TREATMENT OF BULLETIN EPIDERMOLYSIS

Publications (3)

Publication Number Publication Date
IL273407A IL273407A (en) 2020-05-31
IL273407B1 IL273407B1 (en) 2025-05-01
IL273407B2 true IL273407B2 (en) 2025-09-01

Family

ID=65810503

Family Applications (1)

Application Number Title Priority Date Filing Date
IL273407A IL273407B2 (en) 2017-09-22 2018-09-21 Methods and compositions for the treatment of epidermolysis bullosa

Country Status (10)

Country Link
EP (1) EP3684336A4 (de)
JP (1) JP7525396B2 (de)
KR (1) KR102722950B1 (de)
CN (1) CN111182890A (de)
AU (1) AU2018335788B2 (de)
CA (1) CA3076610A1 (de)
EA (1) EA202090814A1 (de)
IL (1) IL273407B2 (de)
MX (2) MX2020002777A (de)
WO (1) WO2019060719A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US12558316B2 (en) 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
IL322149A (en) * 2019-05-03 2025-09-01 Cellphire Inc Materials and methods for manufacturing blood products
KR102125567B1 (ko) 2019-07-02 2020-06-22 한양대학교 에리카산학협력단 식물 엑소좀의 대량 생산 방법
AU2020459825A1 (en) * 2020-07-22 2023-03-16 Osaka University Therapeutic agent for dystrophic epidermolysis bullosa
AU2021327376A1 (en) * 2020-08-21 2023-04-20 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP3971440B1 (de) 2020-09-21 2023-12-27 Brembo S.p.A. Bremsband einer scheibenbremsscheibe sowie scheibenbremsscheibe
CA3217654A1 (en) * 2021-04-23 2022-10-27 Spot Biosystems Ltd. Extracellular vesicles loaded with biomolecules
JP2024531238A (ja) * 2021-08-12 2024-08-29 オンコノヴァ セラピューティクス， インコーポレイテッド がんを処置するための方法および組成物
US12589120B2 (en) 2021-10-12 2026-03-31 Eliksa Therapeutics, Inc. Methods of treating epidermolysis bullosa with cell-free amniotic fluid compositions
EP4694903A1 (de) * 2023-04-11 2026-02-18 Eliksa Therapeutics, Inc. Verfahren zur erhöhung des therapeutischen proteinspiegels und/oder zur verbesserung der zellfunktion mit fruchtwasserzusammensetzungen

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (en) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
US20160184363A1 (en) * 2013-03-13 2016-06-30 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
WO2017123022A1 (ko) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
WO2017122095A1 (en) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
US20170258845A1 (en) * 2013-09-16 2017-09-14 Agency For Science, Technology And Research Methods of Treating Graft Versus Host Disease (GVHD) or Epidermolysis Bullosa (EB)

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184363A1 (en) * 2013-03-13 2016-06-30 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US20170258845A1 (en) * 2013-09-16 2017-09-14 Agency For Science, Technology And Research Methods of Treating Graft Versus Host Disease (GVHD) or Epidermolysis Bullosa (EB)
WO2015138878A1 (en) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
WO2017123022A1 (ko) * 2016-01-12 2017-07-20 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀
WO2017122095A1 (en) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GIMONA, MARIO, ET AL., MANUFACTURING OF HUMAN EXTRACELLULAR VESICLE-BASED THERAPEUTICS FOR CLINICAL USE., 3 June 2017 (2017-06-03) *
HA, DINH, NINGNING YANG, AND VENKATAREDDY NADITHE., EXOSOMES AS THERAPEUTIC DRUG CARRIERS AND DELIVERY VEHICLES ACROSS BIOLOGICAL MEMBRANES: CURRENT PERSPECTIVES AND FUTURE CHALLENGES., 1 July 2016 (2016-07-01) *
MCBRIDE, JEFFREY D., LUIS RODRIGUEZ-MENOCAL, AND EVANGELOS V. BADIAVAS., EXTRACELLULAR VESICLES AS BIOMARKERS AND THERAPEUTICS IN DERMATOLOGY: A FOCUS ON EXOSOMES., 23 June 2017 (2017-06-23) *
SHABBIR, ARSALAN, ET AL., MESENCHYMAL STEM CELL EXOSOMES INDUCE PROLIFERATION AND MIGRATION OF NORMAL AND CHRONIC WOUND FIBROBLASTS, AND ENHANCE ANGIOGENESIS IN VITRO., 13 April 2015 (2015-04-13) *
SUN, DONGMEI, ET AL., EXOSOMES ARE ENDOGENOUS NANOPARTICLES THAT CAN DELIVER BIOLOGICAL INFORMATION BETWEEN CELLS., 6 July 2012 (2012-07-06) *

Also Published As

Publication number Publication date
AU2018335788B2 (en) 2024-08-15
CA3076610A1 (en) 2019-03-28
IL273407A (en) 2020-05-31
MX2020002777A (es) 2020-09-17
JP2020534344A (ja) 2020-11-26
MX2022015753A (es) 2023-01-19
KR102722950B1 (ko) 2024-10-28
CN111182890A (zh) 2020-05-19
EP3684336A4 (de) 2021-06-02
AU2018335788A1 (en) 2020-03-19
JP7525396B2 (ja) 2024-07-30
IL273407B1 (en) 2025-05-01
WO2019060719A1 (en) 2019-03-28
EA202090814A1 (ru) 2020-08-07
KR20200088799A (ko) 2020-07-23
EP3684336A1 (de) 2020-07-29

Similar Documents

Publication Publication Date Title
IL273407B2 (en) Methods and compositions for the treatment of epidermolysis bullosa
JP2020534344A5 (de)
Bullard et al. Fetal wound healing: current biology
ES2601681T3 (es) Nuevos medicamentos de uso tópico basados en ácido hialurónico sulfatado como agente de activación o inhibición de la actividad de las citoquinas
CA2962444C (en) Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
Schreurs et al. Tissue engineering strategies combining molecular targets against inflammation and fibrosis, and umbilical cord blood stem cells to improve hampered muscle and skin regeneration following cleft repair
EP2926819B1 (de) Verfahren zur initiierung von säugerstammzellen und verwendung von chlordioxid bei der herstellung eines arzneimittels zur initiierung von säugerstammzellen
US9840704B2 (en) Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids
Wang et al. Targeting senescent tendon stem/progenitor cells to prevent or treat age-related tendon disorders
Mancini et al. Structure and function of newborn skin
Xu et al. miR-125b-5p delivered by adipose-derived stem cell exosomes alleviates hypertrophic scarring by suppressing Smad2
JPH0635389B2 (ja) デオキシリボヌクレオシドを含有する創傷治療用医薬品組成物
CN108251420A (zh) 抑制人和动物中CTGF基因表达的siRNA、包含其的组合物及其应用
FR2718023A1 (fr) Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
Kim et al. Accelerated wound healing by S-methylmethionine sulfonium: evidence of dermal fibroblast activation via the ERK1/2 pathway
ES2311973T3 (es) Ctgf como objetivo para la terapia de microalbuminuria en pacientes con nefropatia diabetica.
CN114984233B (zh) 一种基于鲵皮肤分泌物的局部给药系统及其应用
Wang et al. Emerging roles of Rab27 proteins: from normal to cancer stem cells
JP2024000505A (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法
CN107840897A (zh) 一种用于治疗骨关节炎的透明质酸镁盐及其制备方法和应用
CN108685883A (zh) 包含柏木醇或其衍生物或其药学上可接受的盐的用于预防或治疗自身免疫疾病的药物组合物
Hyun et al. Strengthening the cellular function of dermal fibroblasts and dermal papilla cells using nanovesicles extracted from stem cells using blue light-based photobiomodulation technology
EP3946330A1 (de) Verfahren zur behandlung von keloid, hypertrophischen narben und/oder hyperpigmentierungserkrankungen
US20240200072A1 (en) Allogeneic Cartilage Regeneration
WO2021252261A1 (en) Compositions and methods for hair follicle regeneration